Actually, we do fund studies of illicit drugs
Whatever you might have heard in the media, we do fund research into illicit psychoactive drugs. Here Dr Kathryn Adcock, Head of Neurosciences and Mental Health at the MRC, explains.
You might have seen in the news today that Professor David Nutt, Professor of Neuropsychopharmacology at Imperial College London, has said that UK funders are unwilling to fund research that uses illicit drugs.
But we agree that recreational drugs may have therapeutic benefits, and we encourage research in this area. That’s why in 2012 we funded Professor Nutt to the tune of over £500,000 for his research into whether psilocybin – the active ingredient in magic mushrooms – can treat major depression. In 2013 we funded his £250,000 project to use psilocybin in schizophrenia research.
And Professor Nutt isn’t the only person we’re funding in this area. Last year, for example, we spent more than £860,000 on studies into the therapeutic use of a cannabis derivative called cannabidiol for psychosis and cannabis dependence. We’re also funding research into whether ketamine can reduce the side effects of electroconvulsive therapy in people being treated for severe depression.
We make our funding decisions via our boards of experts, and decisions are made based on the quality of the research proposal, not on how controversial a topic is. We’re certainly not cautious about funding studies just because they relate to an illegal drug.
So, those researchers out there with a great proposal for research into how recreational drugs can improve health, as well as research into substance abuse and addiction, you know where to come.